RYK is a GPNMB receptor that drives MASH
• Abstract The prevalence of metabolic-dysfunction-associated steatohepatitis (MASH) is rising globally, yet effective treatments remain limited1. • Here we found that systemic or
Gpnmb
• Abstract The prevalence of metabolic-dysfunction-associated steatohepatitis (MASH) is rising globally, yet effective treatments remain limited1. • Here we found that systemic or